Thyroid, the leading journal addressing research in thyroidology, is accepting applications for a new Editor-in-Chief.
Read More
Explore advances for thyroid cancer, hypothyroidism, Graves’ disease, immunotherapy, and more on Feb. 19-20, 2021 during ATA’s virtual meeting.
AbbVie is pleased to introduce the SYNTHROID DELIVERS PROGRAM, a direct-to-patient pharmacy program that offers…
Thyrogen Co-Pay Assistance Program is available to support patient access to Thyrogen. This program helps…
Eisai is pleased to announce that LENVIMATM (lenvatinib)is now approved for the treatment of locally…
Revised label will facilitate use of Thyrogen to greater number of patients for postoperative thyroid…
Woodcliff Lake, NJ, February 2, 2014 – Eisai Inc. announced today that the Phase 3…
From the American Thyroid Association: In collaboration with the Food and Drug Administration (FDA), and…
AstraZeneca is pleased to announce two new clinical trials for patients with differentiated thyroid cancer….
Bayer and Onyx Pharmaceuticals Announce FDA Priority Review Designation of Nexavar® (sorafenib) Supplemental New Drug…
AMERICAN THYROID ASSOCIATION® , ATA® , THYROID® , CLINICAL THYROIDOLOGY® , and the distinctive circular logo are registered in the U.S. Patent and Trademark Office as trademarks of the American Thyroid Association® , Inc.